The scientific journal Nature has published a supplement focussing on multiple sclerosis research.
Today, a group of MPs and members of the House of Lords has launched a report on the barriers people with MS face to finding and staying in work. The report by the All Party Parliamentary Group for MS makes a series of recommendations on how best to support people with MS in the workplace.
Today the MS Trust publishes the findings of its year-long MS Forward View project, looking at how MS services in the UK can deliver equitable, effective and efficient care for everyone living with MS.
The Scottish Medicines Consortium has announced that fampridine (Fampyra) is not a cost effective treatment for MS-related walking problems.
This evening at a ceremony in Windsor we were delighted to announce the winners of the second QuDoS awards, recognising quality in the delivery of MS services.
On Monday 31st October the government published its Work, Health and Disability Green Paper. (A Green Paper is a government consultation document. Its role is to create debate on proposals for new policy or legislation, before committing to a course of action.)
Further analysis of data from a clinical trial has shown that people taking Lemtrada were more likely to have an improvement in disability over the two years of the study, compared to people taking Rebif.
The government are to scrap repeat assessments of people claiming ESA (Employment Support Allowance) if they have a condition that is unlikely to have improved.
Siponimod reduced the risk of progression in secondary progressive MS (SPMS) according to results presented at the ECTRIMS meeting in London on 17 September.